Drug intelligence / Profile preview

C2-R212

Development stage: Unknown
Lead developer: Alvogen Korea

Overview

C2-R212 is a drug developed by Alvogen Korea that was investigated in a Phase III clinical trial for the treatment of dyslipidemia and hypertension. It was studied as a monotherapy component alongside a fixed-dose combination drug, DP-R212, which also included C1-R212. The trial aimed to evaluate its efficacy and safety in patients suffering from both conditions.

Beyond the preview

Go deeper on C2-R212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2-R212.

Explore the full profile